Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

January’s top stories: Profectus Ebola trial, AstraZeneca-Incyte lung cancer drug

Profectus BioSciences began VesiculoVax-vectored vaccine trial, AstraZeneca and Incyte announced combination drug evaluation, SillaJen started Phase III trial for Pexa-Vec. Drugdevelopment-technology.com wraps-up the key headlines from January.

Go Top